<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>A1894</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Albertus Extra Bold";
	panose-1:2 14 8 2 4 3 4 2 2 4;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 6 4 5 2 3 4;}
@font-face
	{font-family:Albertus;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	background:navy;
	font-size:12.0pt;
	font-family:"Tahoma",sans-serif;}
p.FronterPage, li.FronterPage, div.FronterPage
	{mso-style-name:FronterPage;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Para10pt
	{mso-style-name:Para10pt;
	font-family:"Times New Roman",serif;}
p.PrefileFronterTitle, li.PrefileFronterTitle, div.PrefileFronterTitle
	{mso-style-name:PrefileFronterTitle;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:17.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.StylePrefileFronterTitleLeft, li.StylePrefileFronterTitleLeft, div.StylePrefileFronterTitleLeft
	{mso-style-name:"Style PrefileFronterTitle + Left";
	margin-top:0in;
	margin-right:-.2in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:17.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.BillHead
	{mso-style-name:BillHead;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillHeading2
	{mso-style-name:BillHeading2;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillLanguage
	{mso-style-name:BillLanguage;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.HangingAnAct, li.HangingAnAct, div.HangingAnAct
	{mso-style-name:HangingAnAct;
	mso-style-link:"HangingAnAct Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.HangingAnActChar
	{mso-style-name:"HangingAnAct Char";
	mso-style-link:HangingAnAct;
	letter-spacing:.2pt;}
span.11ptChar
	{mso-style-name:11ptChar;
	font-family:"Times New Roman",serif;}
span.BillHeadUnBold
	{mso-style-name:BillHeadUnBold;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.bpuBill, li.bpuBill, div.bpuBill
	{mso-style-name:bpuBill;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:26.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuHeadSpon, li.bpuHeadSpon, div.bpuHeadSpon
	{mso-style-name:bpuHeadSpon;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.bpuHeadSponChar
	{mso-style-name:bpuHeadSponChar;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuIntro, li.bpuIntro, div.bpuIntro
	{mso-style-name:bpuIntro;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuLegislature, li.bpuLegislature, div.bpuLegislature
	{mso-style-name:bpuLegislature;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:24.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuNormText, li.bpuNormText, div.bpuNormText
	{mso-style-name:bpuNormText;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuReprint, li.bpuReprint, div.bpuReprint
	{mso-style-name:bpuReprint;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:22.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.bpuSponsor, li.bpuSponsor, div.bpuSponsor
	{mso-style-name:bpuSponsor;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuState, li.bpuState, div.bpuState
	{mso-style-name:bpuState;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:32.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.charMarlett
	{mso-style-name:charMarlett;
	font-family:Marlett;}
p.ElevenPt, li.ElevenPt, div.ElevenPt
	{mso-style-name:ElevenPt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPage12pt, li.FronterPage12pt, div.FronterPage12pt
	{mso-style-name:FronterPage12pt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageBillHeading, li.FronterPageBillHeading, div.FronterPageBillHeading
	{mso-style-name:FronterPageBillHeading;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.FronterPageNOCAPS, li.FronterPageNOCAPS, div.FronterPageNOCAPS
	{mso-style-name:FronterPageNOCAPS;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times",serif;}
p.FronterPageTBox2, li.FronterPageTBox2, div.FronterPageTBox2
	{mso-style-name:FronterPageTBox2;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageTextBox, li.FronterPageTextBox, div.FronterPageTextBox
	{mso-style-name:FronterPageTextBox;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.FronterSameAs, li.FronterSameAs, div.FronterSameAs
	{mso-style-name:FronterSameAs;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Pg2Footer, li.Pg2Footer, div.Pg2Footer
	{mso-style-name:Pg2Footer;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Style10pt
	{mso-style-name:"Style 10 pt";
	font-family:"Times New Roman",serif;}
p.StyleFronterPage11pt, li.StyleFronterPage11pt, div.StyleFronterPage11pt
	{mso-style-name:"Style FronterPage + 11 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.StyleFronterPageLoweredby3pt, li.StyleFronterPageLoweredby3pt, div.StyleFronterPageLoweredby3pt
	{mso-style-name:"Style FronterPage + Lowered by  3 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	position:relative;
	top:3.0pt;}
p.StyleFronterSameAsPatternSolid100White, li.StyleFronterSameAsPatternSolid100White, div.StyleFronterSameAsPatternSolid100White
	{mso-style-name:"Style FronterSameAs + Pattern\: Solid \(100%\) \(White\)";
	margin:0in;
	margin-bottom:.0001pt;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Style1, li.Style1, div.Style1
	{mso-style-name:Style1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Whereas
	{mso-style-name:Whereas;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
p.bpuWpGraphic, li.bpuWpGraphic, div.bpuWpGraphic
	{mso-style-name:bpuWpGraphic;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.LeftBrackt
	{mso-style-name:LeftBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.RightBrackt
	{mso-style-name:RightBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.Superscript
	{mso-style-name:Superscript;
	font-family:"Albertus",sans-serif;
	font-weight:bold;
	vertical-align:super;}
p.sponUdate, li.sponUdate, div.sponUdate
	{mso-style-name:sponUdate;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.BoldItal
	{mso-style-name:BoldItal;
	font-weight:bold;
	font-style:italic;}
p.amendfooter, li.amendfooter, div.amendfooter
	{mso-style-name:amendfooter;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.HangingSup, li.HangingSup, div.HangingSup
	{mso-style-name:HangingSup;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableBottom, li.HangingTableBottom, div.HangingTableBottom
	{mso-style-name:HangingTableBottom;
	margin-top:0in;
	margin-right:1.0in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableTop, li.HangingTableTop, div.HangingTableTop
	{mso-style-name:HangingTableTop;
	margin-top:0in;
	margin-right:.5in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:8.5in 14.0in;
	margin:1.5in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:8.5in 14.0in;
	margin:1.5in 113.75pt 1.0in 113.75pt;}
div.WordSection2
	{page:WordSection2;}
@page WordSection3
	{size:8.5in 14.0in;
	margin:1.0in 1.75in 67.5pt 2.0in;}
div.WordSection3
	{page:WordSection3;}
-->
</style>

</head>

<body lang=EN-US>

<div class=WordSection1>

<p class=bpuBill><a name=bpuFrontPg></a>ASSEMBLY, No. 1894 </p>

<p class=bpuWpGraphic></p>

<p class=bpuState>STATE OF NEW JERSEY</p>

<p class=bpuLegislature>221st LEGISLATURE</p>

<p class=bpuWpGraphic>  </p>

<p class=bpuIntro>PRE-FILED FOR INTRODUCTION IN THE 2024 SESSION</p>

<p class=bpuIntro>&nbsp;</p>

</div>

<span style='font-size:12.0pt;line-height:120%;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:auto'>
</span>

<div class=WordSection2>

<p class=bpuIntro>&nbsp;</p>

<p class=bpuSponsor>Sponsored by:</p>

<p class=bpuSponsor>Assemblyman  HERB CONAWAY, JR.</p>

<p class=bpuSponsor>District 7 (Burlington)</p>

<p class=bpuSponsor>Assemblywoman  SHANIQUE SPEIGHT</p>

<p class=bpuSponsor>District 29 (Essex and Hudson)</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>SYNOPSIS</p>

<p class=bpuNormText>     Expands exemptions from drug paraphernalia laws to also
exempt certain harm reduction supplies. </p>

<p class=bpuNormText>&nbsp;</p>

<p class=bpuSponsor>CURRENT VERSION OF TEXT </p>

<p class=bpuNormText>     Introduced Pending Technical Review by Legislative
Counsel.</p>

<p class=bpuNormText>   </p>

</div>

<span style='font-size:10.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection3>

<p class=HangingAnAct style='line-height:150%'><span class=BillHead>An Act</span><span
class=HangingAnActChar> concerning harm reduction supplies and amending
N.J.S.2C:36-1, P.L.2011, c.183, and P.L.2021, c.396.</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     <span class=BillHeading2>Be It
Enacted </span><span class=BillLanguage>by the Senate and General Assembly of
the State of New Jersey:</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     1.    N.J.S.2C:36-1 is amended
to read as follows:</p>

<p class=MsoNormal style='line-height:150%'>     2C:36-1.     Drug
paraphernalia, defined; determination.</p>

<p class=MsoNormal style='line-height:150%'>     a.     As used in this act<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>, &quot;drug<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>:</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>Drug</u>
paraphernalia&quot; means all equipment, products and materials of any kind
which are used or intended for use in planting, propagating, cultivating,
growing, harvesting, manufacturing, compounding, converting, producing,
processing, preparing, testing, analyzing, packaging, repackaging, storing,
containing, concealing, ingesting, inhaling, or otherwise introducing into the
human body a controlled dangerous substance, controlled substance analog or
toxic chemical, other than marijuana or hashish, in violation of the provisions
of chapter 35 of this title.  It shall include, but not be limited to:  </p>

<p class=MsoNormal style='line-height:150%'>     (1)   kits used or intended
for use in planting, propagating, cultivating, growing or harvesting of any
species of plant, other than the plant Cannabis sativa L., which is a
controlled dangerous substance or from which a controlled dangerous substance
can be derived;</p>

<p class=MsoNormal style='line-height:150%'>     (2)   kits used or intended
for use in manufacturing, compounding, converting, producing, processing, or
preparing controlled dangerous substances or controlled substance analogs;</p>

<p class=MsoNormal style='line-height:150%'>     (3)   isomerization devices
used or intended for use in increasing the potency of any species of plant,
other than the plant Cannabis sativa L., which is a controlled dangerous
substance;</p>

<p class=MsoNormal style='line-height:150%'>     (4)   <b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>testing
equipment other than fentanyl test strips, used or intended for use
identifying, or in analyzing the strength, effectiveness or purity of
controlled dangerous substances or controlled substance analogs<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>(deleted
by amendment, P.L.    , c.    ) (pending before the Legislature as this bill)</u>;</p>

<p class=MsoNormal style='line-height:150%'>     (5)   scales and balances used
or intended for use in weighing or measuring controlled dangerous substances or
controlled substance analogs;</p>

<p class=MsoNormal style='line-height:150%'>     (6)   <b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>dilutants and
adulterants, such as quinine hydrochloride, mannitol, mannite, dextrose and
lactose, used or intended for use in cutting controlled dangerous substances or
controlled substance analogs<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b>
<u>(deleted by amendment, P.L.    , c.   ) (pending before the Legislature as
this bill)</u>;</p>

<p class=MsoNormal style='line-height:150%'>     (7)   <b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>blenders,
bowls, containers, spoons and mixing devices used or intended for use in
compounding controlled dangerous substances or controlled substance analogs<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>(deleted
by amendment, P.L.    , c.   ) (pending before the Legislature as this bill)</u>;</p>

<p class=MsoNormal style='line-height:150%'>     (8)   capsules, balloons,
envelopes and other containers used or intended for use in packaging small
quantities of controlled dangerous substances or controlled substance analogs;</p>

<p class=MsoNormal style='line-height:150%'>     (9)   containers and other
objects used or intended for use in storing or concealing controlled dangerous
substances, controlled substance analogs or toxic chemicals;</p>

<p class=MsoNormal style='line-height:150%'>     (10) <b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>objects used
or intended for use in ingesting, inhaling, or otherwise introducing cocaine,
nitrous oxide or the fumes of a toxic chemical into the human body, such as (a)
metal, wooden, acrylic, glass, stone, plastic, or ceramic pipes with or without
screens, permanent screens, or punctured metal bowls; (b) water pipes; (c)
carburetion tubes and devices; (d) smoking and carburetion masks; (e) roach
clips, meaning objects used to hold burning material that has become too small
or too short to be held in the hand; (f) miniature cocaine spoons, and cocaine
vials; (g) chamber pipes; (h) carburetor pipes; (i) electric pipes; (j)
air-driven pipes; (k) chillums; (l) bongs; (m) ice pipes or chillers; (n)
compressed gas containers, such as tanks, cartridges or canisters, that contain
food grade or pharmaceutical grade nitrous oxide as a principal ingredient; (o)
chargers or charging bottles, meaning metal, ceramic or plastic devices that
contain an interior pin that may be used to expel compressed gas from a
cartridge or canister; and (p) tubes, balloons, bags, fabrics, bottles or other
containers used to concentrate or hold in suspension a toxic chemical or the
fumes of a toxic chemical<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b>
<u>(deleted by amendment, P.L.    , c.   ) (pending before the Legislature as
this bill).</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>Harm reduction supplies
means <span style='color:#212121'>any materials or equipment used or intended
for use in preventing, reducing, or mitigating the adverse effects associated
with the personal use of controlled dangerous substances, controlled substance
analogs, or toxic chemicals, which harmful effects may include, but are not
limited to, disease transmission and overdose.  Harm reduction supplies
include, but shall not be limited to:  </span>naloxone hydrochloride and other <span
style='color:#212121'>opioid antidotes; test strips and other supplies or
equipment designed to identify or analyze the presence, strength, effectiveness,
or purity of controlled dangerous substances, controlled substance analogs,
toxic chemicals, or other substances used to potentiate or enhance the effects
of controlled dangerous substances, controlled substance analogs, or toxic
chemicals; and supplies or equipment provided by an entity authorized to
provide harm reduction services in accordance with the provisions of P.L.2006,
c.99 (C.26:5C-25 et al.)</span></u>.</p>

<p class=MsoNormal style='line-height:150%'>     b.    In determining whether
or not an object is drug paraphernalia, the trier of fact, in addition to or as
part of the proofs, may consider the following factors:</p>

<p class=MsoNormal style='line-height:150%'>     (1) (a) statements by an owner
or by anyone in control of the object concerning its use;</p>

<p class=MsoNormal style='line-height:150%'>     (b)   the proximity of the
object to illegally possessed controlled dangerous substances, controlled
substance analogs or toxic chemicals;</p>

<p class=MsoNormal style='line-height:150%'>     (c)   the existence of any
residue of illegally possessed controlled dangerous substances, controlled
substance analogs or toxic chemicals on the object;</p>

<p class=MsoNormal style='line-height:150%'>     (d)   direct or circumstantial
evidence of the intent of an owner, or of anyone in control of the object, to
deliver it to persons whom he knows intend to use the object to facilitate a
violation of this act; the innocence of an owner, or of anyone in control of
the object, as to a direct violation of this act shall not prevent a finding
that the object is intended for use as drug paraphernalia;</p>

<p class=MsoNormal style='line-height:150%'>     (e)   instructions, oral or
written, provided with the object concerning its use;</p>

<p class=MsoNormal style='line-height:150%'>     (f)   descriptive materials
accompanying the object which explain or depict its use;</p>

<p class=MsoNormal style='line-height:150%'>     (g)   national or local
advertising whose purpose the person knows or should know is to promote the
sale of objects intended for use as drug paraphernalia;</p>

<p class=MsoNormal style='line-height:150%'>     (h)   the manner in which the
object is displayed for sale;</p>

<p class=MsoNormal style='line-height:150%'>     (i)    the existence and scope
of legitimate uses for the object in the community; <b><span style='font-family:
"Albertus Extra Bold",sans-serif'>[</span></b>and<b><span style='font-family:
"Albertus Extra Bold",sans-serif'>]</span></b></p>

<p class=MsoNormal style='line-height:150%'>     (j)    expert testimony
concerning its use<u>; and</u></p>

<p class=MsoNormal style='line-height:150%'><span style='color:black'>     <u>(k)   any
indicia demonstrating that an object was obtained from or provided by </u></span><u><span
style='color:#212121'>an authorized harm reduction services program in
accordance with the provisions of P.L.2006, c.99 (C.26:5C-25 et al.)</span></u>.</p>

<p class=MsoNormal style='line-height:150%'>     (2)   If an object appears to
be for use, intended for use, or designed for use with cannabis or cannabis
items in accordance with the &quot;New Jersey Cannabis Regulatory, Enforcement
Assistance, and Marketplace Modernization Act,&quot; P.L.2021, c.16 (C.24:6I-31
et al.), the object is presumed to be a lawful cannabis paraphernalia as
defined in section 3 of <b><span style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>that
act<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>P.L.2021,
c.16</u> (C.24:6I-33), and does not alone constitute reasonable articulable
suspicion that the object is a drug paraphernalia, notwithstanding that the
object could also be used with an illegal controlled substance or controlled
substance analog, unless the owner or any other person in proximity to or in
control of the object was in possession of an illegal controlled dangerous
substance or controlled substance analog, or the object was in proximity of an
illegally possessed controlled dangerous substance or controlled substance analog
to indicate its use, intended use, or design for use with that controlled
dangerous substance or controlled substance analog.</p>

<p class=MsoNormal style='line-height:150%'>     c.     Notwithstanding
subsection a. of this section, it shall not be unlawful for a person to use, <u>possess,
distribute,</u> or possess with the intent to use <u>or distribute</u>, a
hypodermic needle or syringe for the personal use of a controlled substance. 
This provision shall extend to a hypodermic syringe or needle that contains a
residual amount <br clear=all style='page-break-before:always'>
of a controlled dangerous substance or controlled substance analog.</p>

<p class=MsoNormal style='line-height:150%'>(cf: P.L.2021, c.403, s.3)</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     2.    Section 1 of P.L.2011,
c.183 (C.2C:36-6.2) is amended to read as follows:</p>

<p class=MsoNormal style='line-height:150%'>     1. a. Notwithstanding any
State law, rule, or regulation to the contrary, a licensed pharmacy <u>or
pharmacist</u> may sell a hypodermic syringe or needle, or any other instrument
adapted for the administration of drugs by injection, to a person over 18 years
of age who presents valid photo identification to demonstrate proof of age or
who otherwise satisfies the seller that he is over 18 years of age, as follows:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   without a prescription
if sold in quantities of 10 or fewer; and</p>

<p class=MsoNormal style='line-height:150%'>     (2)   pursuant to a
prescription issued by a person authorized to prescribe under State law if sold
in quantities of more than 10.</p>

<p class=MsoNormal style='line-height:150%'>     b.    A licensed pharmacy that
provides hypodermic syringes or needles for sale shall also be required to:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   maintain its supply of
such instruments under or behind the pharmacy sales counter<u>, or in another
otherwise-secured place,</u> such that <b><span style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>they<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>the
hypodermic syringes or needles</u> are accessible only to a person standing
behind a pharmacy sales counter <u>or who is authorized to access the
otherwise-secured place</u>; <b><span style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>and<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b></p>

<p class=MsoNormal style='line-height:150%'>     (2)   make available to each
person who purchases any such instrument, at the time of purchase, information
to be developed by the Department of Health to the purchaser, about:</p>

<p class=MsoNormal style='line-height:150%'>     (a)   the safe disposal of the
instrument, including local disposal locations or a telephone number to call
for that information; and</p>

<p class=MsoNormal style='line-height:150%'>     (b)   <b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>substance
abuse<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b>
treatment <u>for substance use disorders</u>, including a telephone number to
call for assistance in obtaining treatment<u>; and</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>(3)   offer each person who
purchases a hypodermic syringe or needle the option of returning the hypodermic
syringe or needle to the pharmacy for safe disposal, without charge</u>.</p>

<p class=MsoNormal style='line-height:150%'>     c.     In addition to any
other provision of law that may apply, a person who purchases a hypodermic
syringe or needle pursuant to subsection a. of this section and sells that
needle or syringe to another person is guilty of a disorderly persons offense.</p>

<p class=MsoNormal style='line-height:150%'>     d.    The Department of
Health, in consultation with the Department of Human Services and the New
Jersey State Board of Pharmacy, may, pursuant to the &quot;Administrative
Procedure Act,&quot; P.L.1968, c.410 (C.52:14B-1 et seq.), adopt rules and
regulations to effectuate the purposes of subsection b. of this section.  The
Department of Health shall make the information <b><span style='font-family:
"Albertus Extra Bold",sans-serif'>[</span></b>that is to be<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> developed
pursuant to subsection b. of this section available to pharmacies<u>,
pharmacists,</u> and purchasers of hypodermic syringes or needles through its
Internet website.</p>

<p class=MsoNormal style='line-height:150%'>(cf: P.L.2012, c.17, s.4)</p>

<p class=MsoNormal style='line-height:150%'>     3.    Section 1 of P.L.2021,
c.396 (C.26:5C-26.1) is amended to read as follows:</p>

<p class=MsoNormal style='line-height:150%'>     1.    As used in P.L.2006,
c.99 (C.26:5C-25 et al.):</p>

<p class=MsoNormal style='line-height:150%'>     &quot;Authorized harm
reduction services&quot; means a suite of harm reduction services, approved by
the Department of Health and provided in a manner that is consistent with State
and federal law, which services shall include, but shall not be limited to:
syringe access, syringe disposal, referrals to health and social services, harm
reduction counseling and supplies including, but not limited to, fentanyl test
strips, and HIV and hepatitis C testing.</p>

<p class=MsoNormal style='line-height:150%'>     &quot;Eligible entity&quot;
means a federally qualified health center, a public health agency, a substance
abuse treatment program, an AIDS service organization, or another entity with
the capacity to provide harm reduction services as determined by the Department
of Health.</p>

<p class=MsoNormal style='line-height:150%'>     &quot;Harm reduction
supplies&quot; means any materials or equipment <b><span style='font-family:
"Albertus Extra Bold",sans-serif'>[</span></b>designed to identify or analyze
the presence, strength, effectiveness, or purity of controlled dangerous
substances or controlled substance analogs, including, but not limited to,
fentanyl test strips; opioid antidotes and associated supplies; and any other
materials or equipment that may be used to prevent, reduce or mitigate the
harms of disease transmission, overdose, and other harms associated with
personal drug use as are designated through<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> 
<u><span style='color:#212121'>used or intended for use in preventing,
reducing, or mitigating the adverse effects associated with the personal use of
controlled dangerous substances, controlled substance analogs, or toxic
chemicals, which adverse effects may include, but are not limited to, disease
transmission and overdose.  Harm reduction supplies include, but shall not be
limited to:  </span>naloxone hydrochloride and other <span style='color:#212121'>opioid
antidotes; test strips and other supplies or equipment designed to identify or
analyze the presence, strength, effectiveness, or purity of controlled
dangerous substances, controlled substance analogs, toxic chemicals, or other
substances used to potentiate or enhance the effects of controlled dangerous
substances, controlled substance analogs, or toxic chemicals; and supplies or
equipment provided by an authorized harm reduction services program in
accordance with the provisions of P.L.2006, c.99 (C.26:5C-25 et al.) and any</span></u>
rules <b><span style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>prescribed<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>promulgated
pursuant to P.L.2006, c.99 (C.26:5C-25 et al.)</u> by the <b><span
style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>Commissioners<b><span
style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b> <u>Commissioner</u>
of Health <b><span style='font-family:"Albertus Extra Bold",sans-serif'>[</span></b>or
Human Services<b><span style='font-family:"Albertus Extra Bold",sans-serif'>]</span></b>.</p>

<p class=MsoNormal style='line-height:150%'>(cf: P.L.2021, c.396, s.1)</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     4.    This act shall take effect
immediately.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:150%'>STATEMENT</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     This bill exempts certain
supplies from State criminal drug paraphernalia laws.</p>

<p class=MsoNormal style='line-height:150%'>     Current law establishes
criminal penalties for possessing, manufacturing, distributing, dispensing, or
advertising drug paraphernalia, which items used in connection with the
production, distribution, and use of illicit drugs.  Current law provides
certain exceptions from the definition of drug paraphernalia for fentanyl
test strips and hypodermic needles and syringes that are sold by a pharmacy.</p>

<p class=MsoNormal style='line-height:150%'>     This bill expands the current
exceptions from the definition of drug paraphernalia to include: 1)
equipment, products used for testing and analyzing a controlled dangerous
substance; 2) testing equipment other than fentanyl test strips, used or intended
for use identifying, or in analyzing the strength, effectiveness or purity of
controlled dangerous substances or controlled substance analogs; 3) dilutants
and adulterants, such as quinine hydrochloride, mannitol, mannite, dextrose and
lactose, used or intended for use in cutting controlled dangerous substances or
controlled substance analogs, which are provided by an entity authorized to
provide harm reduction services; 4) blenders, bowls, containers, spoons and
mixing devices used or intended for use in compounding controlled dangerous
substances or controlled substance analogs, which are provided by an entity
authorized to provide harm reduction services; 5) objects used or intended for
use in ingesting, inhaling, or otherwise introducing cocaine, nitrous oxide or
the fumes of a toxic chemical, other than marijuana or hashish, into the human
body, which are provided by an entity authorized to provide harm reduction
services; and 6) harm reduction supplies. </p>

<p class=MsoNormal style='line-height:150%'>     Under the bill, harm
reduction supplies, means <span style='color:#212121'>any materials or
equipment used or intended for use in preventing, reducing, or mitigating the
adverse effects associated with the personal use of controlled dangerous
substances, controlled substance analogs, or toxic chemicals, which </span>adverse
<span style='color:#212121'>effects may include, but are not limited to,
disease transmission and overdose.  Harm reduction supplies includes, but is
not to be limited to:  </span>naloxone hydrochloride and other <span
style='color:#212121'>opioid antidotes; test strips and other supplies or
equipment designed to identify or analyze the presence, strength,
effectiveness, or purity of controlled dangerous substances, controlled
substance analogs, toxic chemicals, or other substances used to potentiate or
enhance the effects of controlled dangerous substances, controlled substance
analogs, or toxic chemicals; and supplies or equipment provided by an entity
authorized to provide harm reduction services in accordance with the provisions
of P.L.2006, c.99 (C.26:5C-25 et al.)</span>. </p>

</div>

</body>

</html>
